Advanced Joint & Post-Surgical Recovery Protocol
Maximise tissue regeneration after joint surgery or significant tendon/ligament repair by combining the soft-tissue base with a growth-hormone secretagogue stack for IGF-1-driven chondrogenesis and collagen synthesis
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.
Protocol Stack
BPC-157
PrimaryDose
500 mcg
Frequency
2x/day SC
Timing
Morning and evening; SC proximal to the surgical/repair site
Duration
16 weeks
TB-500 (Thymosin Beta-4)
PrimaryDose
5 mg
Frequency
2x/week SC (weeks 1β8), then 1x/week (weeks 9β16)
Timing
Separate from BPC-157 by at least 2 hours
Duration
16 weeks
CJC-1295 (no DAC)
SupportingDose
100 mcg
Frequency
1x/day SC (5 days on, 2 off)
Timing
At night, fasted, with Ipamorelin
Duration
16 weeks
Ipamorelin
SupportingDose
200β300 mcg
Frequency
1x/day SC (5 days on, 2 off)
Timing
At night, fasted, co-injected with CJC-1295
Duration
16 weeks
GHK-Cu
OptionalDose
2 mg SC
Frequency
1x/day SC
Timing
Evening
Duration
16 weeks
Monitoring Parameters
- βSurgeon's rehab milestones and ROM targets β per post-op protocol
- βPain score (NRS 0β10) and swelling β weekly
- βStrength and functional testing aligned to rehab phase β week 4, 8, 12, 16
- βFasting glucose and IGF-1 at baseline and week 8 (GH secretagogue stack)
- βImaging per surgeon (ultrasound/MRI) to confirm graft/repair integrity before progression
Expected Outcomes
Weeks 1β4: Reduced post-operative inflammation and pain, faster early ROM recovery
Weeks 5β10: Accelerated collagen maturation, improved strength relative to standard rehab timelines
Weeks 11β16: Stronger, better-organised repair tissue; smoother return to sport/full load under supervision
Contraindications
- βActive or recent malignancy β GH secretagogues raise IGF-1, which is contraindicated with cancer history without oncology clearance
- βDiabetes or impaired glucose tolerance β CJC-1295/Ipamorelin and especially combined GH axis stimulation raise glucose
- βActive joint infection or unstable/failed surgical repair
- βPregnancy or breastfeeding
- βKnown hypersensitivity to any protocol peptide
Clinical Notes
This is the most aggressive joint protocol and builds directly on the foundation pair. The addition is the GH secretagogue stack: CJC-1295 (no DAC) is a GHRH analogue and Ipamorelin a selective ghrelin-receptor agonist; co-injected at night and fasted they produce a clean, pulsatile GH release that elevates IGF-1 without the blunt elevation of exogenous HGH. IGF-1 is central to chondrocyte proliferation, collagen synthesis and tendon-graft maturation, which is why this stack is reserved for post-surgical and major-repair cases where the regenerative demand is highest. The 5-on/2-off schedule preserves pituitary sensitivity. Because this raises IGF-1 and glucose, baseline labs and oncology/glucose screening are mandatory β this is an advanced protocol, not a starter. Critically, peptides are an adjunct to, never a replacement for, the surgeon's structured rehabilitation; do not progress load faster than the post-op protocol and imaging allow, even if you feel better.
Case Study
Clinical Practice Example
Male, 29, semi-professional footballer, ACL reconstruction (hamstring autograft) plus partial meniscectomy. Wanted to accelerate return to sport without compromising graft integrity. Standard rehab plus BPC-157 500 mcg 2x/day + TB-500 5 mg 2x/week + CJC-1295/Ipamorelin 100/250 mcg nightly (5/2) from week 2 post-op; IGF-1 rose from 180 to 290 ng/mL by week 8, fasting glucose stable. Week 8: quad strength 78% of contralateral (vs ~65% typical), full ROM, no effusion. Week 16: limb symmetry index 94%, MRI confirmed well-incorporated graft, cleared for sport-specific drills ahead of the usual 9-month timeline. No adverse events.